Laboratory or animals. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.
How we read studies and personal accounts ↗Identity
A CBD homologue with a seven-carbon side chain, identified in cannabis in 2019. It is not THCP.
Terms associated with this entry: cannabidiphorol, CBD-C7.
An extra letter does not mean an upgrade
A 2024 receptor comparison found broadly similar profiles for CBD and CBDP; CBD showed somewhat greater CB2 antagonism in that assay. This does not support universal superiority for CBDP.
What the 2026 paper adds
A 2026 study described negative allosteric modulation of CB1, supported by cell assays, mutagenesis and molecular modelling. It also included mice. It was not a therapeutic trial in patients.
The useful question behind “more potent”
Before accepting a comparison, complete the sentence: more potent at producing which response, in which system, and compared with which substance? A headline that leaves out those three pieces offers no interpretable comparison. The interesting task is to follow specific questions, rather than rank abbreviations as though they were quality grades.
What has been studied
These studies have not established a clinical benefit.
Risks and gaps
The selected sources do not establish clinical safety or therapeutic efficacy for CBDP.
Documented forms
| Laboratory standards | Used for receptor assays; not a clinically evaluated formulation. |
|---|
A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.
Experiences
We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.
Conclusion
Its profile should grow with the evidence, not with the size of the promise. To interpret a new claim, first locate the experiment behind it.
Legal context
Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.
Sources
- A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol · Original research
- CBD Versus CBDP: Comparing In Vitro Receptor-Binding Activities · Laboratory study
- Cannabidiphorol (CBDP) acts as a negative allosteric modulator at two distinct sites of cannabinoid receptor 1 · Laboratory study
Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.